Protara Therapeutics, Inc. (TARA)
NASDAQ
Market Cap
$40.25M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
765 of 809
Rank in Industry
419 of 445
Largest Insider Buys in Sector
TARA Stock Price History Chart
TARA Stock Performance
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Insider Activity of Protara Therapeutics, Inc.
Over the last 12 months, insiders at Protara Therapeutics, Inc. have bought $0 and sold $971,719 worth of Protara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protara Therapeutics, Inc. have bought $2.31M and sold $926,908 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,065 shares for transaction amount of $34,810 was made by Shefferman Jesse (CEO and President) on 2022‑08‑11.
List of Insider Buy and Sell Transactions, Protara Therapeutics, Inc.
| 2024-05-31 | Sale | Opaleye Management Inc. | 10 percent owner | 5,824 0.0292% | $2.90 | $16,895 | -5.73% | |
| 2024-05-30 | Sale | Opaleye Management Inc. | 10 percent owner | 9,230 0.0454% | $2.94 | $27,113 | -8.62% | |
| 2024-05-22 | Sale | Opaleye Management Inc. | 10 percent owner | 9,800 0.0481% | $3.02 | $29,596 | -10.17% | |
| 2024-05-21 | Sale | Opaleye Management Inc. | 10 percent owner | 33,000 0.1671% | $3.06 | $100,838 | -7.51% | |
| 2024-05-17 | Sale | Opaleye Management Inc. | 10 percent owner | 70,885 0.3032% | $3.25 | $230,326 | -11.33% | |
| 2024-05-10 | Sale | Opaleye Management Inc. | 10 percent owner | 151,700 0.7648% | $3.11 | $472,424 | -6.21% | |
| 2024-05-09 | Sale | Opaleye Management Inc. | 10 percent owner | 30,600 0.1541% | $3.09 | $94,526 | -4.76% | |
| 2022-12-30 | Sale | Opaleye Management Inc. | director | 15,473 0.1389% | $2.71 | $41,949 | -0.75% | |
| 2022-08-11 | Shefferman Jesse | CEO and President | 9,065 0.0892% | $3.84 | $34,810 | -9.38% | ||
| 2022-06-30 | BESHAR LUKE M | 10,000 0.0939% | $3.10 | $31,000 | +9.56% | |||
| 2022-04-08 | Opaleye Management Inc. | 10 percent owner | 7,791 0.064% | $4.80 | $37,364 | -36.80% | ||
| 2022-04-07 | Opaleye Management Inc. | 10 percent owner | 2,345 0.0203% | $4.74 | $11,123 | -32.68% | ||
| 2022-03-14 | BESHAR LUKE M | 10,000 0.0889% | $4.25 | $42,500 | -21.88% | |||
| 2022-03-10 | BESHAR LUKE M | 10,000 0.0876% | $4.46 | $44,555 | -26.33% | |||
| 2022-01-28 | Opaleye Management Inc. | 10 percent owner | 24,031 0.2099% | $4.96 | $119,271 | -33.47% | ||
| 2021-12-29 | Opaleye Management Inc. | 10 percent owner | 4,500 0.0455% | $6.98 | $31,408 | -44.15% | ||
| 2021-12-28 | Opaleye Management Inc. | 10 percent owner | 7,091 0.063% | $6.36 | $45,090 | -46.00% | ||
| 2021-12-27 | Opaleye Management Inc. | 10 percent owner | 36,700 0.3288% | $6.53 | $239,713 | -47.00% | ||
| 2021-12-23 | Opaleye Management Inc. | 10 percent owner | 1,300 0.0111% | $6.60 | $8,580 | -50.14% | ||
| 2021-12-20 | Opaleye Management Inc. | 10 percent owner | 703 0.006% | $6.49 | $4,562 | -48.66% |
Insider Historical Profitability
<0.0001%
| Opaleye Management Inc. | director | 108696 1.1439% | $1.96 | 15 | 8 | <0.0001% |
| O'Leary Brendan | director | 1387198 12.206% | $1.96 | 1 | 0 | |
| Abingworth LLP | 10 percent owner | 950000 8.3591% | $1.96 | 1 | 0 | |
| Haines Timothy | 950000 8.3591% | $1.96 | 1 | 0 | ||
| Shefferman Jesse | CEO and President | 879441 7.7382% | $1.96 | 1 | 0 | <0.0001% |
| Kobyzev Dmitry | 600000 5.2794% | $1.96 | 1 | 0 | ||
| Pharmstandard International S.A. | 10 percent owner | 600000 5.2794% | $1.96 | 1 | 0 | |
| Marshall Randall | 585600 5.1527% | $1.96 | 0 | 27 | ||
| Birner Hubert | 300000 2.6397% | $1.96 | 1 | 0 | ||
| TVM Life Science Ventures VI GmbH & Co KG | 10 percent owner | 300000 2.6397% | $1.96 | 1 | 0 | |
| Freund John Gordon | 200000 1.7598% | $1.96 | 1 | 1 | ||
| Skyline Venture Partners Qualified Purchaser Fund IV L P | 10 percent owner | 200000 1.7598% | $1.96 | 1 | 1 | |
| BESHAR LUKE M | 198000 1.7422% | $1.96 | 3 | 0 | <0.0001% | |
| Flynn James E | director | 197424 1.7371% | $1.96 | 2 | 1 | |
| Burke Steven Keith | SVP and Chief Medical Officer | 117535 1.0342% | $1.96 | 1 | 0 | |
| Olivo Martin Sebastian | Chief Medical Officer | 14344 0.1262% | $1.96 | 1 | 0 | <0.0001% |
| Eldridge, George Arthur | Sr VP, CFO, Treasr, Asst Secy | 1545 0.0136% | $1.96 | 2 | 0 | |
| Davis Blaine | Chief Financial Officer | 1481 0.013% | $1.96 | 1 | 0 | <0.0001% |
| NOYES TIMOTHY P | President and CEO | 0 0% | $1.96 | 0 | 5 | |
| Gottlieb Daniel Philip | VP Marketing & Bus Development | 0 0% | $1.96 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Opaleye Management Inc | $10.8M | 13.08 | 2.69M | 0% | +$0 | 1.71 | |
| The Vanguard Group | $1.71M | 2.08 | 427,612 | 0% | +$0 | <0.0001 | |
| Boxer Capital, LLC | $839,000.00 | 1.02 | 209,227 | 0% | +$0 | 0.04 | |
| Ikarian Capital LLC | $812,830.00 | 0.98 | 202,701 | +7.44% | +$56,288.30 | 0.23 | |
| Baker Bros Advisors LP | $800,681.00 | 0.97 | 199,671 | 0% | +$0 | 0.01 | |
| Renaissance Technologies | $339,000.00 | 0.41 | 84,600 | -25.33% | -$115,003.55 | <0.01 | |
| Geode Capital Management | $332,519.00 | 0.4 | 82,907 | +5.59% | +$17,603.17 | <0.0001 | |
| Bridgeway Capital Management | $236,590.00 | 0.29 | 59,000 | -7.81% | -$20,050.00 | <0.01 | |
| BlackRock | $123,765.00 | 0.15 | 30,864 | -10.06% | -$13,842.56 | <0.0001 | |
| LINSCO PRIVATE LEDGER CORP | $112,280.00 | 0.14 | 28,000 | +133.33% | +$64,160.00 | <0.0001 | |
| Two Sigma Advisers LP | $108,342.00 | 0.13 | 27,018 | 0% | +$0 | <0.0001 | |
| State Street | $106,666.00 | 0.13 | 26,600 | -13.92% | -$17,243.00 | <0.0001 | |
| Citadel Advisors LLC | $104,051.00 | 0.13 | 25,948 | -31.78% | -$48,468.65 | <0.0001 | |
| Boothbay Fund Management LLC | $90,814.00 | 0.11 | 22,647 | +20.05% | +$15,169.75 | <0.01 | |
| BB&T | $80,200.00 | 0.1 | 20,000 | New | +$80,200.00 | <0.0001 | |
| Two Sigma | $79,189.00 | 0.1 | 19,748 | -21.46% | -$21,641.84 | <0.0001 | |
| Simplex Trading Llc | $71,000.00 | 0.09 | 17,850 | New | +$71,000.00 | <0.01 | |
| BNY Mellon | $71,807.00 | 0.09 | 17,907 | 0% | +$0 | <0.0001 | |
| Northern Trust | $70,540.00 | 0.09 | 17,591 | -2.96% | -$2,149.36 | <0.0001 | |
| TWO SIGMA SECURITIES LLC | $69,746.00 | 0.08 | 17,393 | New | +$69,746.00 | <0.01 | |
| Dimensional Fund Advisors | $48,625.00 | 0.06 | 12,126 | New | +$48,625.00 | <0.0001 | |
| Susquehanna International Group | $44,852.00 | 0.05 | 11,185 | New | +$44,852.00 | <0.0001 | |
| Oppenheimer Holdings | $40,100.00 | 0.05 | 10,000 | New | +$40,100.00 | <0.0001 | |
| Acadian Asset Management | $25,000.00 | 0.03 | 6,314 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $16,000.00 | 0.02 | 3,986 | +447.53% | +$13,077.77 | <0.0001 | |
| UBS | $14,937.00 | 0.02 | 3,725 | +306.66% | +$11,263.90 | <0.0001 | |
| Tower Research Capital | $10,346.00 | 0.01 | 2,580 | -40.53% | -$7,049.72 | <0.0001 | |
| Wells Fargo | $2,286.00 | <0.01 | 570 | +0.18% | +$4.01 | <0.0001 | |
| JPMorgan Chase | $88.00 | <0.01 | 22 | +37.5% | +$24.00 | <0.0001 | |
| Qube Research & Technologies | $8.00 | <0.01 | 2 | 0% | +$0 | <0.0001 | |
| Advisor Group Holdings Inc | $401.00 | <0.01 | 100 | 0% | +$0 | <0.0001 |